Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Real-time Estimate Cboe BZX Other stock markets 10:27:37 2024-05-15 EDT			5-day change	1st Jan Change
2.125 ^USD	-0.23%		+2.83%	-26.10%

05-09	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	04-22	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	04-22	CI
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	04-10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	03-25	MT
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	03-15	MT
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-12	CI
North American Morning Briefing : Inflation Data -2-	03-12	DJ
North American Morning Briefing : Nvidia Ignites -2-	02-22	DJ
BioXcel Therapeutics' BXCL701 Granted FDA Fast-Track Designation to Treat Small Cell Neuroendocrine Prostrate Cancer	02-12	MT
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation	02-12	DJ
BioXcel Therapeutics, Inc. Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer	02-12	CI
Positive Quarterly Earnings Boost Exchange-Traded Funds, Equity Futures Pre-Bell Friday	02-09	MT
BioXcel Therapeutics, Inc. Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of Bxcl701 in Combination with Keytruda®	02-06	CI
BioXcel Therapeutics, Inc. Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine	02-05	CI
BioXcel Therapeutics Aligning With FDA Recommendation on Phase 3 Trial, Agrees to Amended Financing Terms	11-14	MT
BioXcel Therapeutics Shares Sink After Weak 3Q	11-14	DJ
BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BioXcel Therapeutics, Inc. Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer of Adenocarcinoma Phenotype	11-08	CI
BioXcel Therapeutics Shares Rise After Treatment for Schizophrenia-Associated Agitation Gets Medicare Code	23-10-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Highlights

Filters